Glaxo shares slide on earnings blow

GlaxoSmithKline’s difficult year continued today as shares tumbled on a warning that it no longer expects to improve a key measure of earnings.

The drugs giant, which has been at the centre of a bribery probe by Chinese authorities, has been hit by a 10% fall in drug and vaccine sales in the United States, driven by competition from generic products.